Related Experiment Videos
DNA ploidy in endometrial carcinoma: major objective prognostic factor
L C Britton1, T O Wilson, T A Gaffey
1Mayo Medical School, Rochester, MN 55905.
Mayo Clinic Proceedings
|May 1, 1990
Summary
DNA ploidy analysis of endometrial carcinoma reveals diploid tumors have significantly lower relapse rates and better progression-free survival. DNA ploidy is a key prognostic factor for treatment decisions.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Endometrial carcinoma is a common gynecologic malignancy.
- Accurate prognostic factors are crucial for guiding treatment decisions.
Purpose of the Study:
- To investigate the prognostic significance of DNA ploidy in endometrial carcinoma.
- To determine if DNA ploidy is an independent predictor of patient outcomes.
Main Methods:
- Flow cytometry was used to analyze DNA ploidy in paraffin-embedded tumor samples from 256 patients.
- Patient data including tumor stage, grade, invasion depth, and subtype were collected.
- Multivariate analysis was performed to assess independent prognostic factors.
Main Results:
- Diploid DNA patterns were observed in 78% of cases, aneuploid in 17%, and tetraploid in 5%.
- Patients with diploid tumors had a significantly lower relapse rate (10%) compared to nondiploid tumors (39%).
- Four-year progression-free survival was 88% for diploid and 57% for nondiploid tumors (P < 0.001).
- DNA ploidy and histologic subtype remained significant independent predictors in multivariate analysis.
Conclusions:
- DNA ploidy is a major objective prognostic factor for endometrial carcinoma.
- DNA ploidy status can serve as a therapeutic determinant in managing endometrial cancer.
- Histologic subtype also retains significant predictive power for patient outcomes.